export default function ThymosinBeta4FullOverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        Thymosin Beta-4 Full is the complete 43-amino acid protein — the compound behind TB-500, which is a shorter synthetic fragment of it. Most community products labeled &ldquo;TB4&rdquo; are actually TB-500. The full protein has Phase 2 clinical trial data in cardiac repair and dry eye disease — the most advanced human evidence of any thymosin compound — but is significantly more difficult to source and verify than TB-500, and cancer history remains an absolute hard stop for both.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Average Person &mdash; Recovering From Injury</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I have a stubborn tendon or muscle injury that isn&rsquo;t healing the way it should. I keep hearing about TB4 for healing. Is the full protein better than TB-500?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The full protein has actual human clinical trial data</strong><br />The TOPCARE-AMI cardiac repair pilot and Phase 2 dry eye disease trials used full-length thymosin beta-4 — not TB-500. For someone who wants the compound with the most human evidence behind it, the full protein has a better clinical paper trail than the fragment.</li>
          <li><strong>The healing mechanism is broad and well-characterized</strong><br />Full thymosin beta-4 promotes cell migration to injury sites, new blood vessel formation to support tissue repair, and inflammation modulation. Those mechanisms apply across tissue types — tendon, muscle, skin, heart. It&rsquo;s not a narrow drug with a single target.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The Phase 2 cardiac data and the dry eye data were in medically supervised patients with documented conditions — not athletes with tendon pain. The musculoskeletal injury healing use case is an extrapolation from the mechanism, not a separately trialed application. There&rsquo;s also a serious sourcing problem: most products sold as &ldquo;thymosin beta-4&rdquo; from research peptide suppliers are actually TB-500 (the fragment), and without mass spectrometry verification you cannot tell. Full Tβ4 is harder to synthesize, more expensive, and more sensitive to storage conditions. Net: the most human data of any thymosin compound, but that data doesn&rsquo;t directly validate the injury use case most people have in mind.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Athlete &mdash; Accelerating Tissue Repair</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;TB-500 gets a lot of talk in athletic circles. The full thymosin beta-4 protein is what the cardiac repair trials actually used. Does using the real thing give me meaningfully better results?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The full protein has a broader mechanism than TB-500 alone</strong><br />Full thymosin beta-4 includes the actin-sequestering domain (which TB-500 also has) plus additional signaling through what&rsquo;s called integrin-linked kinase activation — a pathway that drives cell survival, blood vessel growth, and tissue remodeling. The fragment does less of this. In theory, the full protein&rsquo;s mechanism is richer.</li>
          <li><strong>The angiogenesis and cell migration effects are relevant to athletic tissue repair</strong><br />Getting blood supply to damaged tissue and mobilizing cells to repair it are the core requirements for healing a hard training-related injury. The mechanism of full thymosin beta-4 maps cleanly onto what athletes need from a repair compound.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Whether the full protein produces meaningfully better results for musculoskeletal repair than TB-500 in athletes is not established by human data. The fragment was specifically developed to isolate the active portion of the full protein — so &ldquo;more complete protein&rdquo; doesn&rsquo;t automatically mean better outcomes in an injury context. There&rsquo;s also a practical problem: getting genuine full-length thymosin beta-4 from a gray-market supplier is unreliable — the molecular weight of the full protein is ~4,964 Da; most community TB4 products are actually TB-500 at ~886 Da. Cancer screening before use is not optional given the angiogenesis mechanism. Net: the &ldquo;superior full protein&rdquo; framing is theoretically interesting but practically complicated, and the TB-500 fragment likely provides most of the relevant activity.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Biohacker &mdash; Regenerative Biology and Cardiac Repair</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;The cardiac repair trial data for full thymosin beta-4 is the most advanced regenerative peptide evidence I know of. What does the ILK signaling and actin regulation biology actually imply for regenerative applications?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The TOPCARE-AMI pilot showed durable cardiac function improvement</strong><br />In the Phase 2 cardiac ischemia pilot, imaging metrics of cardiac function — ejection fraction and wall motion — improved at 3 months and the improvement held at 12-month follow-up. That durability in a cardiac context is significant and goes beyond what most peptide research ever achieves in human trials.</li>
          <li><strong>Integrin-linked kinase signaling is upstream of fundamental cell survival and repair pathways</strong><br />The ILK activation that distinguishes full Tβ4 from TB-500 drives cell survival through the AKT pathway, promotes angiogenesis through VEGF upregulation, and modulates the extracellular matrix. For someone interested in the mechanisms that govern regenerative biology at a systems level, this is a well-characterized and genuinely interesting pathway.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The cardiac trial was a safety and feasibility pilot — it was not powered to prove efficacy, and full clinical development for cardiac repair has been slow. The dry eye disease data is the most commercially advanced application, not cardiac regeneration. Getting pharmaceutical-grade full-length Tβ4 outside a clinical trial context is not practically possible — what gray-market suppliers sell as &ldquo;thymosin beta-4&rdquo; is almost certainly TB-500. Cold chain requirements and proper folding of the 43-amino acid protein make the full compound genuinely harder to handle than simple synthetic peptides. The VEGF upregulation and angiogenesis mechanism means cancer screening is non-negotiable. Net: the most clinically interesting thymosin compound, but the regenerative applications remain investigational and authentic supply is nearly impossible to verify outside pharmaceutical channels.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What Thymosin Beta-4 Full is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>The same as TB-500 — the fragment was developed to isolate part of the full protein&rsquo;s activity; they are different molecular entities</li>
              <li>Proven for musculoskeletal injury in athletes — the Phase 2 data is cardiac repair and dry eye disease, not sport injuries</li>
              <li>Practically accessible with quality confidence — most gray-market &ldquo;TB4&rdquo; is actually TB-500; mass spectrometry is the only verification</li>
              <li>Safe for anyone with cancer history — the angiogenesis mechanism is a hard stop regardless of cancer type or timing</li>
              <li>Available without cold chain requirements — the full 43-AA protein is more storage-sensitive than simple synthetic peptides</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>The most advanced human clinical data of any thymosin peptide — Phase 2 cardiac repair pilot with 12-month durability</li>
              <li>Dry eye disease is the most commercially mature application — topical Tβ4 Phase 2 trials are the furthest along</li>
              <li>A broader mechanism than TB-500 — includes ILK signaling and VEGF upregulation beyond actin sequestration</li>
              <li>The compound behind the TB-500 fragment — understanding the full protein illuminates TB-500&rsquo;s mechanism and limits</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
